{"id":1601,"date":"2022-08-25T14:14:47","date_gmt":"2022-08-25T14:14:47","guid":{"rendered":"https:\/\/salzhauershortt.com\/?p=1601"},"modified":"2025-02-13T22:08:43","modified_gmt":"2025-02-13T22:08:43","slug":"the-fda-is-quietly-targeting-cbd-in-2022","status":"publish","type":"post","link":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/","title":{"rendered":"The FDA is Quietly Targeting CBD in 2022"},"content":{"rendered":"
\n

The Food and Drug Administration (FDA) has consistently taken the position that cannabidiol derived from hemp (CBD) cannot be marketed or sold as a dietary supplement or food. The FDA\u2019s position is based on the fact that CBD has been approved for use in a pharmaceutical drug and therefore cannot legally be sold in any ingestible form. In addition, if a CBD company makes any health or wellness claims (e.g., CBD can help you relax, CBD cures back pain) then the FDA will consider the product an unauthorized drug. The FDA has enforced this position against companies selling CBD by issuing Warning Letters, which, as the name suggests, warns companies regarding the improper sale of adulterated and misbranded foods. Despite the consistency from the FDA, there has been a recent uptick from the agency in sending out Warning Letters to CBD companies.<\/p>\n<\/div>\n

\"\"<\/figure>\n
\n

*note: one letter was sent in 2022 to a company selling delta-8 and is not reflected in this graph.<\/p>\n

As you can see, the Warning Letters spiked in 2019, which coincides with the passage of the 2018 Farm Bill in December 2018. With the rise of Covid, the FDA was preoccupied with the pandemic and the amount of Warning Letters decreased significantly. However, it appears that the FDA is again setting its sights on CBD, with 13 Warning Letters going out in 2022. I would expect that number to increase because the year is not yet complete.<\/p>\n

Warning Letters are a fairly minor enforcement action. However, the FDA also has the authority to levy fines and even refer cases to the Department of Justice. A Warning Letter can also lead to more severe actions from the FDA, as well as harm a company\u2019s reputation and spook investors.<\/p>\n

Because of this uptick in Warning Letters, it\u2019s a good time to reevaluate how to mitigate risks of selling CBD. This requires avoiding any direct or indirect claim that CBD has any health or wellness benefits. Direct claims are along the lines of \u201cCBD cures insomnia\u201d or \u201cCBD can treat anxiety.\u201d Indirect claims can be referencing a study regarding CBD, posting customer reviews indicating that CBD has some medical benefit, or implying in any way that CBD does in fact have some positive health or wellness impact.<\/p>\n

If you are unsure how to mitigate the risks associated with CBD products, feel free to reach out to our\u00a0regulatory attorneys<\/a>\u00a0for more information.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The Food and Drug Administration (FDA) has consistently taken the position that cannabidiol derived from hemp (CBD) cannot be marketed or sold as a dietary supplement or food. The FDA\u2019s position is based on the fact that CBD has been approved for use in a pharmaceutical drug and therefore cannot legally be sold in any […]<\/p>\n","protected":false},"author":3,"featured_media":1603,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[28],"tags":[43,42],"class_list":["post-1601","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal-cannabis-blog","tag-cbd","tag-fda"],"yoast_head":"\nThe FDA is Quietly Targeting CBD in 2022 - SalzhauerShortt<\/title>\n<meta name=\"description\" content=\"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA is Quietly Targeting CBD in 2022\" \/>\n<meta property=\"og:description\" content=\"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"SalzhauerShortt\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T14:14:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-13T22:08:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"563\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Daniel Shortt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniel Shortt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\"},\"author\":{\"name\":\"Daniel Shortt\",\"@id\":\"https:\/\/salzhauershortt.com\/#\/schema\/person\/09be632c7c21ba6112e13107781ca59e\"},\"headline\":\"The FDA is Quietly Targeting CBD in 2022\",\"datePublished\":\"2022-08-25T14:14:47+00:00\",\"dateModified\":\"2025-02-13T22:08:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\"},\"wordCount\":406,\"publisher\":{\"@id\":\"https:\/\/salzhauershortt.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg\",\"keywords\":[\"CBD\",\"FDA\"],\"articleSection\":[\"Legal Cannabis Blog\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\",\"url\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\",\"name\":\"The FDA is Quietly Targeting CBD in 2022 - SalzhauerShortt\",\"isPartOf\":{\"@id\":\"https:\/\/salzhauershortt.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg\",\"datePublished\":\"2022-08-25T14:14:47+00:00\",\"dateModified\":\"2025-02-13T22:08:43+00:00\",\"description\":\"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.\",\"breadcrumb\":{\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage\",\"url\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg\",\"contentUrl\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg\",\"width\":1000,\"height\":563},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/salzhauershortt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA is Quietly Targeting CBD in 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/salzhauershortt.com\/#website\",\"url\":\"https:\/\/salzhauershortt.com\/\",\"name\":\"Salzhauer & Shortt\",\"description\":\"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys\",\"publisher\":{\"@id\":\"https:\/\/salzhauershortt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/salzhauershortt.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/salzhauershortt.com\/#organization\",\"name\":\"Salzhauer Shortt\",\"url\":\"https:\/\/salzhauershortt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/salzhauershortt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Salzhauer-Shortt-P.C.png\",\"contentUrl\":\"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Salzhauer-Shortt-P.C.png\",\"width\":500,\"height\":250,\"caption\":\"Salzhauer Shortt\"},\"image\":{\"@id\":\"https:\/\/salzhauershortt.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/salzhauershortt.com\/#\/schema\/person\/09be632c7c21ba6112e13107781ca59e\",\"name\":\"Daniel Shortt\",\"url\":\"https:\/\/salzhauershortt.com\/index.php\/author\/danielshortt\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The FDA is Quietly Targeting CBD in 2022 - SalzhauerShortt","description":"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/","og_locale":"en_US","og_type":"article","og_title":"The FDA is Quietly Targeting CBD in 2022","og_description":"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.","og_url":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/","og_site_name":"SalzhauerShortt","article_published_time":"2022-08-25T14:14:47+00:00","article_modified_time":"2025-02-13T22:08:43+00:00","og_image":[{"width":1000,"height":563,"url":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg","type":"image\/jpeg"}],"author":"Daniel Shortt","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniel Shortt","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#article","isPartOf":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/"},"author":{"name":"Daniel Shortt","@id":"https:\/\/salzhauershortt.com\/#\/schema\/person\/09be632c7c21ba6112e13107781ca59e"},"headline":"The FDA is Quietly Targeting CBD in 2022","datePublished":"2022-08-25T14:14:47+00:00","dateModified":"2025-02-13T22:08:43+00:00","mainEntityOfPage":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/"},"wordCount":406,"publisher":{"@id":"https:\/\/salzhauershortt.com\/#organization"},"image":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg","keywords":["CBD","FDA"],"articleSection":["Legal Cannabis Blog"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/","url":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/","name":"The FDA is Quietly Targeting CBD in 2022 - SalzhauerShortt","isPartOf":{"@id":"https:\/\/salzhauershortt.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage"},"image":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg","datePublished":"2022-08-25T14:14:47+00:00","dateModified":"2025-02-13T22:08:43+00:00","description":"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys.Serving Oregon, Washington, and New York\u2014delivering results nationwide.","breadcrumb":{"@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#primaryimage","url":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg","contentUrl":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Targeting-Letters-Low-res_779b3e1c2f.jpeg","width":1000,"height":563},{"@type":"BreadcrumbList","@id":"https:\/\/salzhauershortt.com\/index.php\/2022\/08\/25\/the-fda-is-quietly-targeting-cbd-in-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/salzhauershortt.com\/"},{"@type":"ListItem","position":2,"name":"The FDA is Quietly Targeting CBD in 2022"}]},{"@type":"WebSite","@id":"https:\/\/salzhauershortt.com\/#website","url":"https:\/\/salzhauershortt.com\/","name":"Salzhauer & Shortt","description":"Salzhauer & Shortt: Dedicated, efficient, and client-focused attorneys","publisher":{"@id":"https:\/\/salzhauershortt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/salzhauershortt.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/salzhauershortt.com\/#organization","name":"Salzhauer Shortt","url":"https:\/\/salzhauershortt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/salzhauershortt.com\/#\/schema\/logo\/image\/","url":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Salzhauer-Shortt-P.C.png","contentUrl":"https:\/\/salzhauershortt.com\/wp-content\/uploads\/2025\/02\/Salzhauer-Shortt-P.C.png","width":500,"height":250,"caption":"Salzhauer Shortt"},"image":{"@id":"https:\/\/salzhauershortt.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/salzhauershortt.com\/#\/schema\/person\/09be632c7c21ba6112e13107781ca59e","name":"Daniel Shortt","url":"https:\/\/salzhauershortt.com\/index.php\/author\/danielshortt\/"}]}},"_links":{"self":[{"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/posts\/1601","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/comments?post=1601"}],"version-history":[{"count":0,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/posts\/1601\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/media\/1603"}],"wp:attachment":[{"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/media?parent=1601"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/categories?post=1601"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/salzhauershortt.com\/index.php\/wp-json\/wp\/v2\/tags?post=1601"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}